Cargando…

Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas

Recurrences of Hodgkin's Lymphoma (HL) 5 years after the initial therapy are rare. The aim of this study is to report a single centre experience of the clinical characteristics, outcome, and toxicity of pts who experienced very late relapses, defined as relapses that occurred 5 or more years af...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gaudio, Francesco, Giordano, Annamaria, Pavone, Vincenzo, Perrone, Tommasina, Curci, Paola, Pastore, Domenico, Delia, Mario, de' Risi, Clara, Spina, Alessandro, Liso, Vincenzo, Specchia, Giorgina
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2011
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023035/ https://www.ncbi.nlm.nih.gov/pubmed/21253449 http://dx.doi.org/10.1155/2011/707542

Ejemplares similares

Tumor Microenvironment and Microvascular Density in Follicular Lymphoma
por: Tamma, Roberto, et al.
Publicado: (2022)

Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin’s lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study
por: Di Renzo, Nicola, et al.
Publicado: (2020)

Efficacy and safety of netupitant/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkin’s lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation
por: Di Renzo, Nicola, et al.
Publicado: (2021)

Different spatial distribution of inflammatory cells in the tumor microenvironment of ABC and GBC subgroups of diffuse large B cell lymphoma
por: Guidolin, Diego, et al.
Publicado: (2021)

Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine?
por: Coccaro, Nicoletta, et al.
Publicado: (2020)

Acute liver failure as the first manifestation of very late relapsing of Hodgkin's disease
por: Ortín, Xavier, et al.
Publicado: (2010)

The Tumor Microenvironment in Classic Hodgkin’s Lymphoma in Responder and No-Responder Patients to First Line ABVD Therapy
por: Tamma, Roberto, et al.
Publicado: (2023)

Inflammatory microenvironment in classical Hodgkin’s lymphoma with special stress on mast cells
por: Ribatti, Domenico, et al.
Publicado: (2022)

Inflammatory Infiltrate and Angiogenesis in Mantle Cell Lymphoma
por: Annese, Tiziana, et al.
Publicado: (2020)

The Effect of the Tumor Microenvironment on Lymphoid Neoplasms Derived from B Cells
por: Ingravallo, Giuseppe, et al.
Publicado: (2022)

Delayed allergy to acyclovir revealed by lymphocyte proliferation test
por: Albanesi, Marcello, et al.
Publicado: (2018)

Very late relapses in Hodgkin lymphoma treated with chemotherapy with or without radiotherapy: linear pattern and distinct prognostic factors
por: Vassilakopoulos, Theodoros P., et al.
Publicado: (2022)

Correction to: Risk of lymphoma subtypes by occupational exposure in southern Italy
por: Ferri, Giovanni Maria, et al.
Publicado: (2020)

Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements
por: Albano, Francesco, et al.
Publicado: (2010)

Anti-Tr/DNER antibody paraneoplastic cerebellar degeneration preceding a very late relapse of Hodgkin Lymphoma after 12 years
por: Christensen, Peter Broegger, et al.
Publicado: (2021)

Diffuse Large B Cell Lymphoma Arising in Patients with Preexisting Hodgkin Lymphoma
por: Bellitti, Emilio, et al.
Publicado: (2022)

Late relapses in Hodgkin lymphoma – should we search for the needle in the haystack?
por: El‐Galaly, Tarec Christoffer, et al.
Publicado: (2022)

Clonal Hematopoiesis at the Crossroads of Inflammatory Bowel Diseases and Hematological Malignancies: A Biological Link?
por: Cumbo, Cosimo, et al.
Publicado: (2022)

Risk of lymphoma subtypes by occupational exposure in Southern Italy
por: Ferri, Giovanni Maria, et al.
Publicado: (2017)

Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine‐based high‐dose chemotherapy regimen
por: Musso, Maurizio, et al.
Publicado: (2015)

Invasive Fungal Infections in Patients with Hematologic Malignancies (Aurora Project): Lights and Shadows During 18-Months Surveillance
por: Montagna, Maria Teresa, et al.
Publicado: (2012)

Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes
por: Aldoss, Ibrahim, et al.
Publicado: (2021)

Serological Response Following BNT162b2 Anti-Sars-Cov-2 mRNA Vaccination in Hematopoietic Stem Cell Transplantation Patients
por: Attolico, Imma, et al.
Publicado: (2021)

P114: Very late relapses in patients with Hodgkin Lymphoma occuring ≥5 years after initial treament with chemotherapy ± radiotherapy: Treatment strategies and prognostic factors for the outcome
por: Vassilakopoulos, Theodoros P., et al.
Publicado: (2022)

Very Late Relapse of Testicular Tumour in Combination with Renal Cancer and Their Retroperitoneoscopic Removal
por: Murányi, Mihály, et al.
Publicado: (2011)

Very Late Relapse in Breast Cancer Survivors: a Report of 6 Cases
por: Omidvari, Shapour, et al.
Publicado: (2013)

Relapsed/Refractory Hodgkin Lymphoma
por: Sheikh, Semira, et al.
Publicado: (2018)

P1084: CHECK-POINT INHIBITORS IN PATIENTS WITH RELAPSE/REFRACTORY HODGKIN’S LYMPHOMA: A RETROSPECTIVE ANALYSYS BY THE RETE EMATOLOGICA PUGLIESE (REP).
por: Gaudio, F., et al.
Publicado: (2022)

Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma
por: Pellegrini, Cinzia, et al.
Publicado: (2017)

Very Late Relapse of Acute Promyelocytic Leukemia 17 Years after Continuous Remission
por: Sakurai, Masatoshi, et al.
Publicado: (2018)

Very late relapse of high-grade osteosarcoma: A case report and review of the literature
por: Kaneuchi, Yoichi, et al.
Publicado: (2020)

Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience
por: Moretti, Marina, et al.
Publicado: (2022)

Hodgkin’s lymphoma: post- autologous transplantation consolidation therapy
por: Merli, Francesco, et al.
Publicado: (2020)

Inflammatory Cells in Diffuse Large B Cell Lymphoma
por: Tamma, Roberto, et al.
Publicado: (2020)

Changing patterns of relapse in Hodgkin's disease.
por: Duchesne, G., et al.
Publicado: (1989)

Impact of Bone Marrow Aspirate Tregs on the Response Rate of Younger Newly Diagnosed Acute Myeloid Leukemia Patients
por: Delia, Mario, et al.
Publicado: (2018)

A case of nodular sclerosis Hodgkin’s lymphoma repeatedly relapsing in the context of composite plasma cell-hyaline vascular Castleman’s disease: successful response to rituximab and radiotherapy
por: Falchi, Lorenzo, et al.
Publicado: (2007)

P18: DARATUMUMAB (D) PLUS BORTEZOMIB (V) AND DEXAMETHASONE (D) AS SALVAGE THERAPY FOR PATIENTS WITH REFRACTORY/RELAPSED MULTIPLE MYELOMA (RRMM): INITIAL FOLLOW-UP OF AN ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE BY “RETE EMATOLOGICA PUGLIESE”
por: Mele, G, et al.
Publicado: (2022)

P17: DARATUMUMAB (D) PLUS LENALIDOMIDE (R) AND DEXAMETHASONE (D) AS SALVAGE THERAPY FOR PATIENTS WITH REFRACTORY-RELAPSED MULTIPLE MYELOMA (RRMM): INITIAL FOLLOW-UP OF AN ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE BY “RETE EMATOLOGICA PUGLIESE”
por: Mele, G, et al.
Publicado: (2022)

Very Late Local Relapse of Ewing's Sarcoma of the Head and Neck treated with Aggressive Multimodal Therapy
por: Thariat, J., et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_nie7pqieu55948bbg8jf43s0fj